PMID- 29062594
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 2167-4868 (Print)
IS  - 2167-4868 (Electronic)
IS  - 2167-4868 (Linking)
VI  - 5
IP  - 2
DP  - 2017 Jun
TI  - New Drugs and New Posterior Delivery Methods in CME.
PG  - 160-168
LID - 10.1007/s40135-017-0134-3 [doi]
AB  - PURPOSE: To discuss the characteristics, indications and adverse events (AEs) of 
      sustained-release corticosteroid devices for the treatment of cystoid macular 
      edema (CME). RECENT FINDINGS: Ozurdex(R) is approved for the treatment of diabetic 
      macular edema (DME), retinal vein occlusion related-CME and noninfectious 
      posterior uveitis (NIPU). It releases dexamethasone over a maximum period of 6 
      months making repeated intravitreal injections necessary for recurrent CME. 
      Iluvien(R) releases fluocinolone for up to 36 months and is effective for the 
      treatment of chronic DME. Retisert(R) (Bausch & Lomb, Rochester, NY) also releases 
      fluocinolone, and is approved for chronic NIPU. Both Iluvien(R) and Retisert(R) are 
      non-biodegradable devices and are highly associated with cataract and glaucoma. 
      SUMMARY: Long-acting intraocular corticosteroid formulations offer a more 
      predictable drug-release profile and reduced dosing frequency in comparison to 
      conventional formulations of the same compounds but the risk-benefit ratio must 
      be taken into consideration previous to the implantation of those devices.
FAU - de Oliveira Dias, Joao Rafael
AU  - de Oliveira Dias JR
AD  - Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, 
      900 NW 17 Street, Miami, FL, USA, 33136.
FAU - Nunes, Renata Portella
AU  - Nunes RP
AD  - Federal University of Sao Paulo - Paulista Medical School, Department of 
      Ophthalmology, Rua Botucatu 821, Sao Paulo-SP, Brazil, 04023-062.
FAU - Goldhardt, Raquel
AU  - Goldhardt R
AD  - Bascom Palmer Eye Institute, Department of Ophthalmology, University of Miami, 
      900 NW 17 Street, Miami, FL, USA, 33136.
LA  - eng
GR  - R01 EY026174/EY/NEI NIH HHS/United States
PT  - Journal Article
DEP - 20170407
PL  - United States
TA  - Curr Ophthalmol Rep
JT  - Current ophthalmology reports
JID - 101605578
PMC - PMC5650193
MID - NIHMS866490
OTO - NOTNLM
OT  - cystoid macular edema
OT  - dexamethasone intravitreal implant
OT  - diabetic macular edema
OT  - fluocinolone acetonide
OT  - noninfectious posterior uveitis
OT  - retinal vein occlusion
COIS- Conflict of Interest Raquel Goldhardt, Renata Portella Nunes, and Joao Rafael de 
      Oliveira Dias declare no conflict of interest.
EDAT- 2017/10/25 06:00
MHDA- 2017/10/25 06:01
PMCR- 2018/06/01
CRDT- 2017/10/25 06:00
PHST- 2017/10/25 06:00 [entrez]
PHST- 2017/10/25 06:00 [pubmed]
PHST- 2017/10/25 06:01 [medline]
PHST- 2018/06/01 00:00 [pmc-release]
AID - 10.1007/s40135-017-0134-3 [doi]
PST - ppublish
SO  - Curr Ophthalmol Rep. 2017 Jun;5(2):160-168. doi: 10.1007/s40135-017-0134-3. Epub 
      2017 Apr 7.